Abstract
Psychiatry is rather far away from the therapeutic ideal (Ehrlich’s therapia magna sterilisans): to achieve immediate and complete success in all patients with the disease for which the therapy is indicated (specific efficacy) with no undesired side effects (safety). Currently available psychiatric therapies achieve at best only moderate specific efficacy and safety, so therapy research in psychiatry is badly needed. The main tool for this is the controlled clinical trial. However, the vast number of trial types and designs indicates that there is no ideal for all questions, but only designs which are more or less appropriate for a specific question. Furthermore, a controlled clinical trial goes beyond the individual’s therapeutic help insofar as it is an experimental procedure for gaining new knowledge and a more rational basis for improvement of therapy. According to the Helsinki/ Tokyo Declaration this means a greater need for getting valid informed consent than in routine therapy. However, it is precisely from patients with psychiatric disorders that informed consent may be a particular problem. Although some psychiatric disorders may destroy the capacity of a patient to understand a given piece of information and to give valid consent, all psychiatrists know that this is, in contrast to common public opinion, by no means true of all psychiatric patients. Rather, in a considerable number of psychiatric patients the competency for full informed consent is reduced only transiently and/or partially, and in other patients full competency is maintained (Fletcher et al. 1985; Helmchen 1986a,b; Helmchen and Winau 1986).
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Angst J, Hippius H, Woggon B et al. (1989) Consensus conference on the methodology of clinical trials in antidepressants. Pharmacopsychiatry 22: 3–7
BMJFFG (Der Bundesminister für Jugend, Familie, Frauen und Gesundheit) (1987) Bekanntmachung von Grundsätzen für die ordnungsgemäße Durchführung der Klinischen Prüfung von Arzneimitteln. Bundesanzeiger no 243, p 16617, 30 Dez 1987
Fletcher JC, Dommel FW Jr, Cowell DD (1985) Consent to research with impaired human subjects. IRB: A Review of Human Subjects Research 7 (6): 1–6
Helmchen H (1986a) Aufklärung, Einwilligung. In: Müller C (ed) Lexikon der Psychiatrie, 2nd edn. Springer, Berlin Heidelberg New York, pp 79-80, 221 - 222
Helmchen H (1986b) Ethische Fragen in der Psychiatrie. In: Kisker KP, Lauter H, Meyer J-E, Müller C, Strömgren E (eds) Psychiatrie der Gegenwart, vol 2: Krisenintervention, Suizid, Konsiliarpsychiatrie. Springer, Berlin Heidelberg New York, pp 310–368
Helmchen H, Winau R (eds) (1986) Versuche mit Menschen. De Gruyter, Berlin, p 391
Helmchen H, Kanowski S, Koch HG (1989) Forschung mit dementen Kranken: Forschungsbedarf und das Problem der Einwilligung. Eth Med 1: 83–98
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Helmchen, H. (1990). Ethical Problems and Design of Controlled Clinical Trials. In: Benkert, O., Maier, W., Rickels, K. (eds) Methodology of the Evaluation of Psychotropic Drugs. Psychopharmacology Series, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75370-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-75370-1_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75372-5
Online ISBN: 978-3-642-75370-1
eBook Packages: Springer Book Archive